A novel charged trinuclear platinum complex effective against cisplatin-resistant tumours: Hypersensitivity of p53-mutant human tumour xenografts

British Journal of Cancer

Volumn 80, Issue 12, 1999, Pages 1912-1919

  Pratesi, G ^a   Perego, P ^a   Polizzi, D ^a   Righetti, S C ^a   Supino, R ^a   Caserini, C ^a   Manzotti, C ^b   Giuliani, F C ^b   Pezzoni, G ^b   Tognella, S ^b   Spinelli, S ^b   Farrell, N ^c   Zunino, F ^a  

^a Istituto Nazionale per lo Studio   (Italy)

^b Boehringer Mannheim Italia SpA   (Italy)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

Author keywords

Cisplatin; Drug resistance; Multinuclear platinum complex; p53 mutation

Indexed keywords

BBR 3464; CISPLATIN; CYTOTOXIC AGENT; PLATINUM COMPLEX; PROTEIN P53; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CHEMOSENSITIVITY; CONTROLLED STUDY; DNA REPAIR; DRUG CONFORMATION; DRUG DESIGN; DRUG DNA BINDING; DRUG POTENCY; DRUG RESISTANCE; DRUG STRUCTURE; HUMAN; HUMAN CELL; INTRAVENOUS DRUG ADMINISTRATION; LUNG CARCINOMA; MOUSE; NONHUMAN; OSTEOSARCOMA CELL; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR REGRESSION; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL CYCLE; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENES, P53; HUMANS; MALE; MICE; MICE, NUDE; MODELS, MOLECULAR; MOLECULAR CONFORMATION; MUTATION; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; OSTEOSARCOMA; POLYMORPHISM, SINGLE-STRANDED CONFORMATIONAL; TRANSPLANTATION, HETEROLOGOUS;

EID: 0032788573     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690620     Document Type: Article

References (30)

1. Brachmann RK, Vidal M and Bocke JD (1996) Dominant-negative p53 mutations selected in yeast hit cancer hot spots. Proc Natl Acad Sci USA 93: 4091-4095
2. Caserini C, Pratesi G, Tortoreto M, Bedogné B, Carenini N, Supino R, Perego P, Righetti SC and Zunino F (1997) Apoptosis as a determinant of tumor sensitivity to topotecan in human ovarian tumours: preclinical in vitro/in vivo studies. Clin Cancer Res 3: 955-961
3. Chu G (1994) Cellular responses to cisplatin. J Biol Chem 269: 787-790
4. Crul M, Schellens JHM, Beijnen JH and Maliepaard M (1997) Cisplatin resistance and DNA repair. Cancer Treat Rev 23: 341-366
5. Eastman A (1987) The information, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol Ther 34: 155-166
6. Farrell N (1993) Nonclassical platinum antitumour agents: perspective for design and development of new drugs complementary to cisplatin. Cancer Invest 11: 578-589
7. Farrell N (1995a) DNA binding and chemistry of dinuclear platinum complexes. Comments in Inorganic Chemistry 16: 373-389
8. Farrell N (1996) DNA binding of dinuclear platinum complexes. In: Advances in DNA Sequence Specific Agents, Hurley I.H, Chaires JB (eds). pp. 187-216, JAI Press Inc
9. Farrell N, Appleton TG, Qu Y, Roberts JD, Soares Fontes AP, Skov KA, Wu P and Zou Y (1995b) Effects of geometric isomerism and ligand substitution in bifunctional dinuclear platinum complexes on binding properties and conformational changes in DNA. Biochemistry 34: 15480-15487
10. Farrell N, Qu Y, Kasparkova J, Brabee V, Valsecchi M, Menta E, Di Domenico R, Conti M, Da Re G, Lotto A und Spinelli S (1997) Chemical studies and DNA binding of charged polynuclear platinum complexes. Proc Am Ass Cancer Res 38: 310
11. Fink D, Nebel S, Aebi S, Zheng H, Cenni B, Nehmé A, Christen RD and Howell SB (1996) The role of DNA mismatch repair in platinum drug resistance. Cancer Res 56: 4881-4886
12. Harris CC (1996) Structure and function of the p53 tumour suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst 88: 1142-1455
13. Hecker D, Page G, Lohrum M, Weiland S and Scheidtmann KH (1996) Complex regulation of the DNA-binding activity of p53 by phosphorylation: differential effects of individual phosphorylation sites on the interaction with different binding motifs. Oncogene 12: 953-961
14. Hickman JA (1996) Apoptosis and chemotherapy resistance. Eur J Cancer 32A: 921-926
15. Johnson A, Qu Y, Van Houten B and Farrell N (1992) B→Z-DNA conformational changes induced by a family of bis(platinum) complexes. Nucleic Acids Res 20: 1697-1703
16. Kastan MB, Canman CE and Leonard CJ (1995) P53, cell cycle and apoptosis implications for cancer. Cancer Met Rev 14: 3-15
17. Kelland LR (1994) The molecular basis of cisplatin sensitivity/resistance. Eur J Cancer 30A: 725-727
18. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T (1994) p53 stains and the efficacy of cancer therapy in vivo. Science 266: 807-810
19. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ and Kohn KW (1997) Characterization of the p53 tumour suppressor pathway in cell lines of the National Cancer Institute Anticancer Drug Screen and correlations with the growth inhibitory potency of 123 anticancer agents. Cancer Res 57: 4285-4300
20. Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC and Zunino F (1996) Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res 56: 556-562
21. Perego P, Righetti SC, Supino R, Delia D, Caserini C, Carenini N, Bedogne' B, Broome E, Krajewski S, Reed JC and Zunino F (1997) Role of apoptosis and apoptosis-related proteins in the cisplatin-resistant phenotype of human tumor cell lines. Apoptosis 2: 540-548
22. Perego P, Caserini C, Gatli L, Carenini N, Romanelli S, Supino R, Colangelo D, Viano I, Leone R, Spinelli S, Pezzoni G, Manzotti C, Farrell N and Zunino F (1999) A novel trinuclear platinum complex overcomes cisplatin resistance in an osteosarcoma cell system. Mol. Pharmacol 5: 528-534
23. Righetti SC, Della Torre G, Pilotti S, Menard S, Ottone F, Colnaghi MI, Pierotti MA, Lavarino C, Cornarotti M, Oriana S, Bohm S, Bresciani GL, Spatti G and Zunino F (1996) A comparative study of p53 gone mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma. Cancer Res 56: 689-693
24. Rolley N, Butcher S and Milner J (1995) Specific DNA binding by different classes of human p53 mutants. Oncogene 11: 763-770
25. Supino R, Righetti SC, Magnani I, Bottiroli G and Prosperi F. (1996) Modulation and cell cycle distribution of mutant p53 protein in a human small-cell lung carcinoma cell line after exposure to cytotoxic agents. Cell Pharmacol 3: 253-260
26. Vogelstein B and Kinzler KW (1994) X-rays strike p53 again. Nature 370: 174-175
27. Wang XW, Yeh H, Schaeffer L, Roy R, Moncollin V, Egly J-M, Wang Z, Freidberg EC, Evans MK, Taff BG, Bohr VA, Weeda G, Hoeijmakers JHJ, Forrester K and Harris CC (1995) p53 modulation of TFHH-associated nucleotide excision repair activity. Nat Genet 10: 188-195
28. Workman P, Balmain A, Hickman JA, McNally NJ, Mitchison NA, Pierrepoint CG, Raymond R, Rowlatt C, Stephens TC and Wallace J (1988) UKCCCR guidelines for the welfare of animals in experimental neoplasia. Br J Cancer 58: 109-113
29. Wu P, Kharatishvili M and Farrell N (1996) A circular dichroism study of ethidium bromide binding to Z-DNA induced by dinuclear platinum complexes. J Inorg Biochem 63: 9-16
30. Zunino F, Perego P, Pilotti S, Pratesi G, Supino R and Arcamone F (1997) Role of apoptotic response in cellular resistance to cytotoxic agents. Pharmacol Ther 76: 177-185